How Much Semaglutide Do I Inject for Effective Weight Loss?

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The amount you inject is determined by your prescriber and printed on your pharmacy label, and there is no general figure that safely substitutes for it. That is not evasion — it is the specific place where this category produces documented harm. The FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products, arising from patients measuring and self-administering incorrect doses and from clinicians miscalculating doses. What this article can do is explain what determines the number and why the units confuse people.

The Approved Strengths Exist; Your Strength Is Individual

Wegovy injection is supplied at 0.25, 0.5, 1, 1.7 and 2.4 mg, plus Wegovy HD at 7.2 mg approved March 19, 2026. Presentations include single-dose pens, single-dose syringes, and a single-patient-use FlexTouch pen containing 9.6 mg/3 mL that delivers four 2.4 mg doses.

Ozempic, a type 2 diabetes product with no weight-management indication, has a recommended maintenance dosage of 0.5, 1 or 2 mg once weekly with 2 mg as its maximum. Its presentations include multi-dose pens and single-dose prefilled syringes at 0.25, 0.5 and 1 mg per 0.5 mL, four per carton.

Knowing the labeled range tells you what exists. It does not tell you where you belong in it, which depends on your product, your escalation history, your tolerability and your prescriber's judgement.

Why the Units Cause Errors

Approved pen presentations deliver a fixed labeled dose, so the patient is not converting anything. A vial-and-syringe presentation is different: the label states a concentration in milligrams per millilitre, and the volume drawn has to correspond to the prescribed dose.

Insulin syringes are marked in units rather than millilitres, and semaglutide is not dosed in insulin units. Mixing those scales is one of the recognised routes to a tenfold error.

Concentration also varies between compounded preparations, so a volume that was correct with one preparation may be badly wrong with another. That is precisely why the FDA encourages patients to talk with their prescriber or compounder about how to measure and administer the intended dose.

What the Escalation Is For

The labeled escalation exists to manage tolerability. Nausea, vomiting, diarrhea, abdominal pain and constipation are the most common adverse reactions in this class and the most common reason people discontinue. Starting low reduces them.

It is not a race. Study 8 in the Wegovy label ran 72 weeks and STEP 1 ran 68 weeks, with weight curves still separating late in both. Time at a tolerated strength contributes more to the outcome than reaching the top of the range quickly.

The Wegovy label added a Severe Gastrointestinal Adverse Reactions subsection in its 10/2025 revision, and semaglutide is not recommended in patients with severe gastroparesis. Escalation decisions have to account for that.

Higher Is Not Automatically Better

Within the Ozempic label, a trial in 959 patients comparing 1 mg with 2 mg reported mean body weight changes at week 40 of −5.6 kg and −6.4 kg, and states that the difference between arms in body weight change was not statistically significant. Gastrointestinal adverse reactions were more frequent on 2 mg.

In the weight-management range there is a clearer dose-response — Study 8 reported −18.8% at 7.2 mg versus −15.5% at 2.4 mg — but the increment from 2.4 mg to 7.2 mg was smaller than the increment from placebo to 2.4 mg.

Meanwhile the FDA has received adverse event reports that may relate to prescribing beyond the approved label: more product in a single dose, more frequent dosing, or faster escalation, with some events serious enough to require hospitalization.

What to Do Instead of Guessing

Read your pharmacy label and the instructions for use that shipped with your specific presentation. They are product-specific, and a single-dose pen, a multi-dose FlexTouch pen and a vial are not handled the same way.

If anything about the measurement is unclear, contact the dispensing pharmacy before administering. The FDA lists the absence of a reachable licensed clinician among its telehealth red flags precisely because this is when patients need one.

And report problems. The agency encourages healthcare professionals, patients and compounders to report adverse events or quality problems through its MedWatch programme.

Questions That Get You a Useful Answer

What product and concentration am I holding, and what volume corresponds to my prescribed dose? What device am I using, and does it deliver a fixed dose or require measurement?

What is the plan for the next strength, and what would delay it? Which symptoms should prompt a call rather than waiting for the next appointment?

How will response be assessed beyond weight — blood pressure, glycemic markers, symptom burden, nutritional adequacy? Those answers, from the person holding your prescription, are what a number from an article cannot provide.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much semaglutide should I inject?

That is determined by your prescriber and printed on your pharmacy label. There is no general figure that safely applies, because it depends on your product, its concentration, your escalation history and your tolerability. The FDA has documented adverse events, some requiring hospitalization, that may relate to patients measuring and self-administering incorrect doses of compounded injectable semaglutide.

What are the approved semaglutide injection strengths?

Wegovy injection is supplied at 0.25, 0.5, 1, 1.7 and 2.4 mg, plus Wegovy HD at 7.2 mg approved March 19, 2026. Ozempic, a type 2 diabetes product without a weight-management indication, has a recommended maintenance dosage of 0.5, 1 or 2 mg once weekly with 2 mg as its labeled maximum. Where an individual sits within these ranges is a clinical decision.

Why do dosing errors happen with compounded preparations?

Because a vial-and-syringe presentation requires the patient to convert a prescribed dose in milligrams into a volume, using a stated concentration that varies between preparations. Insulin syringes are marked in units rather than millilitres, and semaglutide is not dosed in insulin units. The FDA has received multiple reports of adverse events, some requiring hospitalization, linked to such errors.

Will a higher dose give me faster results?

Not reliably, and it carries real risk. In an Ozempic trial of 959 patients, mean body weight change at week 40 was −5.6 kg on 1 mg and −6.4 kg on 2 mg, a difference the label states was not statistically significant, with more gastrointestinal adverse reactions on 2 mg. The FDA has documented serious adverse events linked to dosing beyond approved labels.

Who should I ask if I am unsure about my dose?

The dispensing pharmacy and your prescriber, before administering anything. The FDA specifically encourages patients to talk with their healthcare provider or compounder about how to measure and administer the intended dose. The instructions for use shipped with your particular presentation are the authoritative document, and they differ between pens, syringes and vials.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.